MYO (YK-11) functions as an active myostatin inhibitor and as a SARM. It is one of the newest discoveries and is orally administered. Myostatin is a protein which inhibits or limits muscle cell growth. By inhibiting myostatin the actual amount of muscle that your can build is increased. The normal genetic limit is raised if you will
The thing that makes MYO (YK-11) so interesting and desirable is the fact that it possesses this dual mechanism of action (both SARM & myostatin inhibitor). While there are compounds that work strictly as a SARM and some that work strictly as a myostatin inhibitor, MYO (YK-11) affords you the opportunity to experiment and research with a compound that very effectively acts as both.
Studies have shown MYO (YK-11) to be significantly more anabolic & androgenic than the steroid dihydrotestosterone (DHT) – WITHOUT the adverse side effects of DHT, such as hair loss and prostate enlargement.
MYO (YK-11)
Dosage
ALL REFERENCES OF USE ARE FOR RESEARCH SUBJECTS AND NOT HUMANS
Concentration: 10mg/mL
Volume: 30mL
A moderate dose of 5mg – 10mg per day of MYO (YK-11) is recommended for most users. Each bottle has 30ml with an average dose been around 1ml (1 full dropper squirt). Each bottle will last around 30 days.
Ingredients/ HPLC Purity Report
MYO: (17-alpha,20E) 17,20-[(1-methoxyethylidene)bis(oxy)] 3-oxo-19-norpregna-4,20-diene 21-carboxylic acid methyl ester, Food-grade USP glycol, food-grade ethyl alcohol and essential oils.
CLICK HERE TO DOWNLOAD CURRENT HPLC REPORT
Storage
Cool and dark space like a cupboard or pantry.
Medical Referances
- Kanno, Y, Kusakabe, T, Saito, N, Kikkawa, S, Takahashi, K, Azumaya, I, Nemoto, K & Kato, K n.d., ‘Improved synthesis and determination of the biologically active diastereomer of yk11’, MolBank, vol. 2020, no. 2
- Kanno, Y. (2013). Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression. https://www.ncbi.nlm.nih.gov/pubmed/23995658
- Kanno, Y. (2011). (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11) is a partial agonist of the androgen receptor